ArticleBMC cancer2025
ADAMTS2 mediates epithelial‒mesenchymal transition and inflammation in high-grade serous ovarian cancer: a study based on bioinformatic analyses and experiments.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe importance of epithelial‒mesenchymal transition (EMT) in tumour invasion and metastasis in high-grade serous ovarian cancer (HGSOC) has been highlighted in numerous studies, but genetic biomarkers for predicting EMT in HGSOC are still lacking.
methodsThe role of EMT hallmarks and the relationship between EMT and the tumour microenvironment in HGSOC were examined based on transcriptomic data from 366 HGSOC patients in the TCGA dataset via the GSVA algorithm, the ESTIMATE method and Pearson correlation analyses. Furthermore, machine learning was applied to determine key EMT signatures and classify EMT subtypes. Moreover, the role of the key EMT signature ADAMTS2 in the behaviour and EMT process of HGSOC cells was detected via western blot, CCK8, transwell, wound healing and immunofluorescence assays.
resultsThe expression of EMT hallmarks (EMT score) was significantly associated with the progression, immune microenvironment and prognosis of HGSOC patients. Different machine learning algorithms identified MMP2, ADAMTS2, FN1, THBS2, C3ORF80, FAP and POSTN as key EMT-related signatures in HGSOC. Finally, qPCR, western blotting and IHC staining consistently revealed elevated expression of ADAMTS2 in five ovarian cancer tissues from HGSOC patients and five normal ovarian epithelial tissues from five uterine prolapse patients. Further in vitro experiments revealed that ADAMTS2 knockdown inhibited cell proliferation, migration, and invasion as well as the expression of TNF-α, IL-1β and EMT markers (E-cadherin, N-cadherin, SLUG, and TWIST1), whereas ADAMTS2 overexpression promoted the above cellular behaviours and increased the expression of TNF-α, IL-1β and EMT markers.
conclusionOur study presents a new classifier to predict EMT and the immune microenvironment in HGSOC and identifies ADAMTS2 as a novel regulator of the EMT process. These findings might promote the development of EMT-related immunotherapeutic strategies for HGSOC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.